Spike Protein News and Research

RSS

Preclinical study from NIH/Moderna: Correlates of SARS-CoV-2 immunity in non-human primates

Researchers in the United States have shown that the antibody response induced by the Moderna mRNA-1273 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a correlate of immune protection against coronavirus disease 2019 (COVID-19) in non-human primates.

22 Apr 2021

Researchers aim to better understand clinical features associated with COVID-19 mortality

To better understand the COVID-19 clinical feaures associated with mortality, an interdisciplinary team of researchers has investigated important factors and their influence on a patient’s death.

22 Apr 2021

B.1.1.7 variant 45% more infectious than wild-type SARS-CoV-2, but can be effectively contained by BNT162b2 vaccine

The SARS-CoV-2 B.1.1.7 variant, also called the UK variant, was identified in London as well as in Southeast and East of England in December 2020. Since its emergence, the UK variant has undergone several mutations that have been said to have altered its infectivity and transmissibility in the community. The B.1.1.7 variant is defined by 17 mutations, several of which are located in the SARS-CoV-2 spike protein that mediates viral attachment and entry into human cells.

21 Apr 2021

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Researchers in the United States have developed adenovirus vectors that may be more effective at generating immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than those used in the vaccines that are currently being rolled out to help combat the coronavirus disease 2019 (COVID-19) pandemic.

21 Apr 2021

Argonne's Advanced Photon Source guided the development of new COVID-19 vaccine now in trials

Human clinical trials have begun on a new vaccine candidate that may protect against not only SARS-CoV-2, the virus that causes COVID-19, but against at least two of the variants emerging around the world.

21 Apr 2021

SARS-CoV-1 utilizes ORF3a protein to trigger viral release

Scientists in the USA – from the Johns Hopkins University and the University of Maryland – have recently uncovered the mechanism by which SARS-CoV-1 is released from the infected cells.

21 Apr 2021

What do we know about the origin and evolution of SARS-CoV-2?

A new study examines the origin and continuing evolution of SARS-CoV-2 in the human and animal co-hosts in an attempt to help prepare for future destructive outbreaks.

21 Apr 2021

Immune escape by SARS-CoV-2 mutations acquired in mink

A new study, published in Cell Reports, suggests that SARS-CoV-2 may have acquired such immune evasion mutations during its transmission in farmed mink.

21 Apr 2021

Researchers explore cost-effective identification method for novel SARS-CoV-2 variants

In a new study, a rapid and cost-effective method of detecting known variants of concern has been developed utilizing capillary electrophoresis, allowing local facilities to screen for and track SARS-CoV-2 variants of concern and implement reactionary procedures.

21 Apr 2021

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

21 Apr 2021

Antibody response induced by mRNA vaccination differs from natural SARS-CoV-2 infection

Researchers tested the antibodies elicited from mRNA vaccination and compared them to those from natural SARS-CoV-2 infection. They found the vaccine did not have antibodies to the virus nucleocapsid protein but had potent RBD antibodies.

21 Apr 2021

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

A new study led by Hans-Martin Jäck of the Friedrich-Alexander University Erlangen-Nuremberg in Germany engineered clusters of neutralizing monoclonal antibodies using a transgenic mouse model. A unique characteristic for the antibodies was the different ways it bound to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the overall reduction in the viral spread for human ACE2.

21 Apr 2021

Seroprevalence studies monitoring SARS-CoV-2 among vaccinees require more than spike assays

Researchers in the United States have shown that an antibody test measuring host reactivity to the nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may better detect natural infection among vaccinated individuals than an assay that measures reactivity to the viral spike protein.

21 Apr 2021

Children develop strong, long-lasting immunity following SARS-CoV-2 infection

Researchers in the UK have conducted a study that may explain why children who become infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) do not generally develop severe coronavirus disease 2019 (COVID-19).

20 Apr 2021

Can an immunosuppressive cancer drug promote SARS-CoV-2 entry into host cells?

A new study shows that rapamycin, an immunosuppressive drug used in some cancers, and its analogs, may have an undesirable effect on viral entry into the host cells. This finding could inform their use to treat symptomatic COVID-19.

20 Apr 2021

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

A team of international scientists recently demonstrated that antibodies generated in response to the DNA vaccine INO-4800 can effectively neutralize some of the recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as G614, 501Y.V1, and 501Y.V2.

20 Apr 2021

Study examines SARS-CoV-2 seropositivity in healthy young adults and risk of reinfection

New research has been published in The Lancet Respiratory Medicine, which focuses on evaluating the effect of SARS-CoV-2 seropositivity on the possibility of developing SARS-CoV-2 infection in a young and healthy population. This study is based on the longitudinal prospective cohort study that involves the COVID-19 Health Action Response for Marines (CHARM).

20 Apr 2021

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

To monitor antibody level duration of vaccine-induced immune responses, a team of researchers in the U.S. – at Diacarta, University of California and VA Healthcare System, and the Franciscan University of Steubenville – evaluated the feasibility of using a single drop of fingerstick blood collected with flocked swabs for quantitative antibody response evaluation after COVID-19 vaccination.

20 Apr 2021

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

A small study, previously posted to the medRiv preprint server in early March, was recently published in the journal Science Immunology. The now peer-reviewed research led by E. John Wherry of the University of Pennsylvania Perelman School of Medicine finds people previously exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produced a more robust immune response after receiving the first — but not the second mRNA vaccine.

19 Apr 2021

Researchers manufacture the SARS-CoV-2 RBD in pichia

Researchers in the United States and India have developed a high-volume, low-cost platform for manufacturing vaccines to protect against different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

19 Apr 2021

Spike Protein News and Research

Preclinical study from NIH/Moderna: Correlates of SARS-CoV-2 immunity in non-human primates

Researchers aim to better understand clinical features associated with COVID-19 mortality

B.1.1.7 variant 45% more infectious than wild-type SARS-CoV-2, but can be effectively contained by BNT162b2 vaccine

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Argonne's Advanced Photon Source guided the development of new COVID-19 vaccine now in trials

SARS-CoV-1 utilizes ORF3a protein to trigger viral release

What do we know about the origin and evolution of SARS-CoV-2?

Immune escape by SARS-CoV-2 mutations acquired in mink

Researchers explore cost-effective identification method for novel SARS-CoV-2 variants

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

Antibody response induced by mRNA vaccination differs from natural SARS-CoV-2 infection

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

Seroprevalence studies monitoring SARS-CoV-2 among vaccinees require more than spike assays

Children develop strong, long-lasting immunity following SARS-CoV-2 infection

Can an immunosuppressive cancer drug promote SARS-CoV-2 entry into host cells?

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

Study examines SARS-CoV-2 seropositivity in healthy young adults and risk of reinfection

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

Researchers manufacture the SARS-CoV-2 RBD in pichia

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News